Logo image
Back
Pharmacological Treatment of Obesity
Book chapter

Pharmacological Treatment of Obesity

Amie A. Ogunsakin and Ayotunde O. Dokun
Nutrition and Diabetes, pp.117-129
CRC Press, 2
2019
DOI: 10.1201/b22121-7

View Online

Abstract

The prevalence of obesity and overweight has risen substantially in the past few decades. It is a public health problem that is associated with significant increase in morbidity and mortality, and a reduction in health-related quality of life [1,2]. Obesity is defined by the World Health Organization (WHO) based on body mass index (BMI). BMI is defined as an individual’s weight in kilograms divided by height in meters squared. A BMI between 18.5 and 25 is considered to be a normal weight, a BMI between 25 and 30 is classified as overweight, and a BMI of more than 30 is considered obese [3,4]. Among Asians, a BMI of 23 or higher is overweight, and a BMI of 27 or higher is obese, due to increased incidence of obesity-related complications at lower BMI.
 Enhances Glucose Dependent Insulin Secretion Bariatric Surgery Severe Hepatic Impairment NAFLD Rapid Acting Insulin Common Adverse Drug Effects GIP Receptor Real Time Continuous Glucose Monitoring Moderate Hepatic Impairment Weight Loss Medications Long Chain Acyl CoA Moderate Renal Impairment IGF-1 Receptor Naltrexone ER Intravenous Glucose Tolerance Insulin Lispro Protamine Suspension Comprehensive Lifestyle Modification End Stage Renal Disease Amp Activate Protein Kinase Long Term Weight Loss Chronic Weight Management Bupropion ER

Details

Metrics

18 Record Views
Logo image